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ABSTRACT 
Metallothionein overexpression prolongs grafts survival in the early 
phase of pancreatic islet transplantation 
Xiaoyan Li 
December 17, 2002 
Pancreatic islet transplantation is a very promising treatment for type I diabetes. 
Many clinical trials have failed due to early islet loss and immune rejection. Reactive 
oxygen species (ROS) have been demonstrated to be involved in graft damage during 
transplantation. Metallothionein (MT) is an inducible antioxidant protein. Prior studies in 
our laboratory have shown that overexpression of MT in beta-cells reduces DNA damage 
and diabetes induced by streptozotocin (STZ), which damages beta cells by generating 
ROS. Therefore in this study we examined whether overexpression of MT in beta cells is 
beneficial to pancreatic islet transplantation. Isolated MT transgenic and normal FVB 
islets were transplanted under the kidney capsule of Balb/c mice that were treated with 
STZ to induce severe diabetes. We found that diabetic mice transplanted with MT islets 
maintained near normal glucose levels for 16.2 ±2.S2 days while those animals 
transplanted with control islets maintained normal glucose values for only 8.36 ±1.67 
days (p<0.01). To determine whether the early benefit ofMT was due to protection from 
early islet loss or from immune rejection, islets were transplanted into same strain mice, 
thereby free of immune rejection. Under these conditions MT islets maintained much 
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higher insulin content than control islets. To assess the possible mechanism .of MT 
benefit isolated FVB and MT islets were exposed to hypoxia (1 % 02, 5% C02 and 94% 
N2). Compared to control islets, MT decreased cell death and reduced ROS production 
during hypoxia. Moreover, after isolated islets were treated with a nitric oxide donor (S-
nitro-N-acetyl-penicillamine) MT reduced NO induced cell death. By 
immunohistochemistry in allografts of FVB and MT islets MT was found to markedly 
reduce the production of nitrotyrosine. These data demonstrated that MT could prolong 
graft survival in pancreatic islet transplantation. The protective mechanism may be 
reduction of ROS production or protection from ROS induced beta cell death. 
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Diabetes mellitus is a metabolic disorder characterized by glucose intolerance and 
hyperglycemia. In the United States, between 6%-7% of population equating to about 16 
million people are suffering from this disease and every year over 105 billion dollars are 
spent on its treatment (Olefsky 2001). It is projected that the prevalence of diabetes in the 
United States will increase to approximately 9% by 2025. Elevated blood glucose level in 
diabetes is associated with an increased risk of developing microvascular diseases, 
principally retinopathy, nephrophathy, and neuropathy. Due to these long-term 
complications, diabetes has caused an enormous burden of morbidity. To date diabetes is 
the leading cause of blindness, amputations and end-stage renal disease and the sixth 
leading cause of death in the United States. But unfortunately all current drug therapies 
for diabetes including intensive insulin therapy do not provide sufficiently tight control of 
blood glucose to avoid the late devastating complications of this disease( 1998; 1993). 
Islet transplantation has become accepted as an alternative therapy for treatment of 
type 1 diabetes. Compared to whole pancreas transplantation, islet transplantation is not 
only a much less invasive procedure but also a procedure much safer and less costly. It 
may be possible to induce immune tolerance of the engrafted islets by pretreating them in 
culture or by pretreating the recipient with donor antigen. It is also possible to use 
cryopreserved pancreatic islets (Warnock et al. 1991) rather than fresh islets or whole 
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pancreas which normally are very limited resources. It has been proven, that clinical islet 
transplantation, when successful, is capable of maintaining excellent metabolic control in 
the absence of hypoglycemia and stopping the progression of clinical long-term 
complications(Boker et at. 2001). But over the years this approach has had a poor record 
of accomplishment in achieving independence from exogenous insulin - approximately 
12% of allotransplanted patients achieved insulin independence for over 7 days(White et 
al. 2001). It has been noticed that the percentage of long term graft survival in islet 
transplantation is much lower than whole-pancreas transplantation. Pancreas graft 
survival for more than one year is respectively 82%, 74% and 76% when the organ was 
implanted after the kidney, simultaneously with kidney, or alone while the islet graft 
survival after one year is less than 10%(White et al. 2001). However a more recently 
published study illustrated that islet transplantation is still a very encouraging approach 
for diabetes treatment. Shapiro and his colleagues (Ryan et al. 2002) established the 
Edmonton protocol. This method relied on long term application of immunosuppressors 
and required more than one donor pancreas for one recipient, however this method was 
more successful-80% of transplanted patients were insulin independent for more than 1 
year. 
The consistent achievement of long-term success in clinical islet transplantation is 
limited by the islet mass that can be effectively engrafted and that can maintain function. 
Two important factors: early islet loss immediately after transplantation and relatively 
late-occurred immune rejection may account for the islet graft failure after islet 
allotransplantation. The early events leading to graft loss are termed primary non-
function (PNF) or early islet loss. This might be an essential determinant for the success 
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of islet transplantation(Brendel et al. 1999) because a majority of islet grafts are damaged 
immediately after transplantation. PNF could result from implantation of an inadequate 
number of functional islets or inflammatory reactions elicited by the interaction between 
the implanted islets and components of the blood stream(Bennet et al. 2000; Bennet et al. 
1999) or immune components residing in the local organ (Bottino et al. 1998). This 
interaction leads to generation of proinflammatory cytokines, nitric oxide and reactive 
oxygen species (ROS), and thereby cytotoxic destruction to the islet graft (Davalli et al. 
1996). It has been clearly demonstrated that local activation of liver macrophages(Steiner 
et al. 1997; Kroncke et al. 1993) and endothelial cells (Steiner et al. 1997; Kroncke et al. 
1993) can mediate PNF by releasing cytokines and nitric oxide in intraportal islet 
allotransplantation. In the rat islet transplantation model, nitric oxide is considered the 
main islet-toxic agent from allogeneic or syngeneic macrophages(Stevens et al. 1995). In 
addition to local nonspecific inflammatory reactions, islet graft also suffers from an 
initial period of hypoxic ischemia after transplantation. The engrafted islets are 
essentially avascular tissue that won't have enough blood supply before the completion of 
revascularization to the host· organ. Revascularization requires over one week (Menger 
et al. 1992b). Therefore the oxygen tension within the islet graft is relatively low 
(Carlsson et al. 2001c) in the early stage of islet transplantation. PNF might be initiated 
by this ischemic microenviroment because ischemia followed by reperfusion is a 
condition known to produce detrimental ROS in transplanted organs (Li et al. 1997; 
Petrowsky et al. 1995; Land et al. 1994; Nakao et al. 1994). 
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The damaging effects of ROS on pancreatic islets have been widely investigated in 
diabetes (Xenos et al. 1994; Horio et al. 1994; Brenner et al. 1993; Suarez-Pinzon et al. 
1997; Xu et al. 1999) as well as in islet transplantation (Stevens et al. 1996; Karsten et ai, 
2001; Mendola et al. 1989), It has been shown that the exposure of isolated human 
(Hadjivassiliou et al. 1998) and rodent islets(Malaisse et al. 1982d; Xu et at. 1999b; 
Hadjivassiliou et al. 1998) or beta cell lines (Zhang et al. 1995) to ROS markedly inhibits 
cell functions including beta cell insulin biosynthesis and secretion, or results in beta cell 
apoptosis and necrosis. Pancreatic beta cells are much more susceptible to ROS 
destruction than other cell types such as those in kidney and liver. The most striking 
evidence is that pancreatic islets are highly sensitive to the destruction of two beta-cell 
toxins, alloxan and streptotozocin (STZ). Both compounds are widely used to produce 
diabetes and their relatively selective damage to beta cells is thought to act through 
generation of ROS including superoxide radicals, nitric oxide radicals and hydrogen 
peroxide(Grankvist et al. 1981a; Takasu et al. 1991). Some other studies also proved that 
pancreatic beta cells have several times higher sensitivity than kidney, muscle, or liver 
cells to the damage of superoxide radical (Burkart et al. 1992), hydrogen peroxide 
(Brunk et al. 1995) and nitric oxide (Eizirik et al. 1994). Further, quantitative studies of 
ROS scavengers in pancreatic beta cells indicate that the sensitivity of islets is due to 
inadequacy of ROS detoxifying systems. Compared with liver, the total islet superoxide 
dismutases (SOD) is less than 30% (Grankvist et at. 1981 b). Glutathione peroxidase and 
catalase in the beta cell are less than 2% of liver(Grankvist et al. 1981 b; Welsh et ai, 
1995; Malaisse et ai, 1982; Johansson & Borg 1988). This deficit of ROS detoxifying 
systems may contribute significantly to the deterioration of islet cells in type 1 diabetes 
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and probably to the islet graft loss after transplantation. Recent data have shown the 
successful improvement of early islet transplant survival by various antioxidant 
combinations such as a-tocopherol (Burkart et at. 1995) and other vitamins(Winter et at. 
2002). Consequently we hypothesize that increasing ROS defenses specifically in beta 
cells may benefit islet transplantation. 
To test our hypothesis, we selected metallothionein (MT) as our candidate 
antioxidant because MT is an efficient ROS scavenger. MT is a cysteine-rich protein 
involved in zinc homeostasis and metal detoxification(Klaassen & Liu 1997). MT also 
appears to play important roles in ROS protection. MT has been shown to be an 
extraordinarily efficient ROS scavenger protecting from hydroxyl radicals(Malaisse et al. 
1982; Schnedl et ai. 1994), nitric oxide radicals (Schwarz et al. 1995) and superoxide 
radicals(Rocic et al. 1997; Kumari et al. 1998; Schwarz et al. 1995). MT protects against 
many agents known to act through ROS, including hydrogen peroxide, radiation, 
glutathione depletors, adriamycin, and xanthine oxidase(Sato & Bremner 1993). By using 
this molecule, we have produced two lines of transgenic mice with overexpression of MT 
in pancreatic beta cells on the FVB mouse strain. We found that the MT trans gene had no 
deleterious effect on beta cell structure or function. But overexpression of MT was very 
effective in protecting FVB mice from diabetes induced by streptozotocin (Chen et al. 
2001). Therefore in the present study we are further testing the potential effect of MT on 
islet transplantation. We want to know whether an increased ROS defense system in beta 
cells is beneficial for graft survival in islet transplantation. 
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CHAPTER II 
MATERIALS and METHODS 
Animals 
Transgenic mice were established on FVB mice with the overexpression of human 
MT II gene by standard transgenic techniques. This transgene was specifically expressed 
in pancreatic beta cells because it was driven by a human insulin promoter. The 
transgenic mice or islets were designated as HMT -1 and the control FVB mice or islets 
were designated as FVB. 
Chemicals 
Streptozotocin, collagenase (type V), Histopaque 1077 and metallothionein were 
obtained from Sigma (S1. Louis, MO). Hank's balanced salt solution (HBSS), RPMI 1640 
medium, and fetal bovine serum (FBS) were supplied by Gibco BRL (Rockville, MD). . 
Rat insulin standard was bought from Linco (S1. Charles, MO). Rabbit antiserum to 
guinea pig insulin, was purchased from BioGenex (San Ramon, CA). Monoclonal anti-
Nitrotyrosine antibody was supplied by Cayman (Ann Arbor, MI). 5-(6)-chloromethyl-
2', 7' -dichlorodihydrofluorescein diacetate (CM-H2DCFDA) was purchased from 
Molecular Probes (Eugene, OR). Alarmablue was purchased from Biosource 
International (Camarillo, CA). 
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The isolation procedure was based on a modification of the method of Gotoh et al 
(Gotoh et al. 1985). Mice were anesthetized with avertin at the dose of 6mg/g body 
weight via intraperitoneal injection. The pancreas was inflated with 3 ml of 1.55 mg/ml 
collagenase Type V and incubated at 37°C for 20 min. The digest was resuspended in 10 
mL Histopaque 1077, overlaid with 10 ml of HBSS and centrifuged at 700 x g for 20 min 
at 10°C. Most of the gradient, excluding the pellet was collected and washed 3 times 
with cold HBSS. Islets were then handpicked in RPMI 1640 medium supplemented with 
10 % fetal bovine serum and 100 V/ml penicillin and 100 Ilg/ml streptomycin. Islets were 
maintained in suspension culture in RPMI 1640 medium at 37°C and 5 % CO2• 
Allotransplantation 
400 FVB or HMT -1 islets were transplanted under both kidney capsules (200 
each) according to a modification of the procedure of Montana et al (Montana et al. 
1993b). Recipient mice were male Balb/c mice purchased from Jackson Laboratory (Bar 
Harbor, Maine). The Balb/c mice, at the age between 8-12 weeks, were injected with STZ 
(ip. 220mg/kg) for 1 to 3 days to induce diabetes. Only the mice with blood glucose range 
from 350mg/dl to 500mgldl were selected as recipients for following transplantation 
surgery. After recipient mice were anesthetized via ip. injection with 10 ul/g of a solution 
containing 10 mg/ml ketamine and 3.2 mg/ml xylazine, the left side mouse kidney was 
first externalized through a small incision and kept moist with saline. An incision was 
made near the posterior pole of the kidney. 200 islets were picked into a gel-loading 
pipette tip (0.5 mm diameter) mounted on a l-cc Hamilton syringe (Reno, NV, VSA) and 
allowed to settle. The tip was inserted through an incision beneath the kidney capsule and 
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the islets were gently forced out of the tip. The body wall and the skin were closed with 
sutures. Then the transplantation to the right side kidney was performed by the same 
procedure. After transplantation, the tail blood glucose levels of the transplanted mice 
were monitored every other day. Graft failure was defined as a return of hyperglycemia 
(blood glucose> 250 mg/dl) on two consecutive measurements. Grafts in some recipients 
were recovered 5 days after transplantation and sectioned for H&E and nitrotyrosine 
staining. 
Syngeneic transplantation 
50 FVB and HMT -1 islets were transplanted separately under each kidney capsule 
in a same normal FVB mouse. 6 days later, grafts were recovered and homogenized in 
acid ethanol (23 ethanol: 2 HCI: 75 H20, v/v/v) for insulin extraction. The preserved 
insulin content in the islet grafts was measured by an anti-insulin antibody coated tube 
RIA kit (Diagnostic Products) and rat insulin standard. 
Immunohistochemistry for nitrotyrosine and insulin 
Islet graft was fixed in 10% formaldehyde in 0.1 molll phosphate buffer (pH 7.2), 
dehydrated in an ascending graded series of ethanol, and subsequently infiltrated with 
paraffin. Serial section were cut at 5 Ilm, mounted on polylysine-coated slides, and then 
deparaffinized in xylenes and a descending graded series of ethanol. For nitrotyrosine 
staining, slides were treated with target retrieval solution (Dako corporation), followed by 
M.O.M mouse Ig blocking regent (Vector Laboratories). Nitrotyrosine monoclonal 
antibody (Cayman) was added on the slides at the concentration of 10 Ilg/ml and 
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incubated overnight at room temperature. After 3 washes in phosphate-buffered saline, 
slides were incubated with the biotinylated anti-mouse IgG reagent, followed by ABC 
reagent and developed with DAB as chromagen. The slides without primary antibody 
treatment were used as negative control. 
For insulin staining, sections were treated with rabbit anti-guinea pIg insulin 
antibody diluted I to 100 and incubated for 90 min at 37°C. After 4 washes in phosphate 
buffered saline, slides were incubated with the appropriate biotin-labeled second antibody 
followed by peroxidase labeled streptavidin and developed with DAB as chromagen. 
Hyooxia in vitro studies 
Isolated FVB and HMT-l islets were cultured in a 96-well plate placed in a sealed 
hypoxic chamber saturated with 1 % 02, 5% C02 and 94% N2 for 24h, 48h, and 72h 
respectively. Cell viability was assessed by measuring islet metabolism as indicated by 
alamar blue absorbance. The data for cell viability were represented as percentages of the 
viabilities of control cells which were cultured under normal condition. ROS production 
in islets after hypoxia 2 or 7 hr was measured with fluorescence dye (CM-H2DCFDA) 
(Molecular Probes). Islets treated with 24h hypoxia were picked for 
immunohistochemistry for insulin and nitrotyrosine. 
Nitric oxide in vitro studies 
Isolated FVB and HMT -1 islets were exposed to different concentrations of a nitric 
oxide donor, S-nitro-N-acetyl-penicillamine (SNAP). Glucose stimulated insulin 
secretion was tested by static assay on 96-well tissue culture microplates and insulin 
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levels were measured with anti-insulin antibody coated RIA kit. Apoptotic and necrotic 
DNA were detected by an anti-histone biotin/anti-DNA POD ELISAplus kit (Roche). All 
values were normalized to islet total DNA measured with picogreen DNA quantification 
kit (Molecular Probes). 
Assays of insulin secretion. insulin content and DNA content 
Insulin secretion was measured by static assay on 96-well tissue-culture 
microplates. For each well 6-10 islets were hand picked into modified KRB (Krebs-
Ringer bicarbonate buffer containing the designated concentration of glucose and 
supplemented with 10mM Hepes, pH 7.4 and 0.1% BSA) containing 3 mM glucose at 
37°C. After two washes in 3 mM glucose KRB the islets were incubated for consecutive 
30 min incubations in 3 and 20 mM glucose KRB. To determine islet insulin content, 
islets were sonicated in 150 ~l lOmM Tris HCI, ImM EDTA, Img/ml RIA grade BSA, 
pH 7.0 for 30 seconds. Fifty ~l of the solution was used to extract islet insulin with 100 
~l acid ethanol (75 ethanol / 2 concentrated HCI / 23 H20, v/v/v) at 4 °C overnight. The 
remainder of the sonicate was digested with an equal volume of 200 ~g/ml proteinase K 
in 100 mM Tris HCl, pH 8.5, 5 mM EDTA, 0.2 % SDS at 55°C for 2 hours and used for 
islet DNA quantification with picogreen using a kit from Molecular Probes. Insulin was 
measured with the coated tube RIA kit from Diagnostic Products and rat insulin 
standards. 
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Islet fluorescence measurement of ROS 
Both hypoxia treated or untreated islets were loaded with 1 ~M 5-(6)-chloromethyl-
2', 7' -dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Molecular Probes, Eugene, 
OR) for 30 min. After islets were washed, fluorescence intensity of each islet was 
measured using an excitation wavelength of 485 nm and an emission wavelength of 530 
nm. Each islet in different groups was sampled using an Olympus IX70 inverted 
microscope equipped with a digital cooled CCD camera and ImagePro image analysis 
software (Media Cybernetics, Silver Spring, MD) under same parameters. Fluorescence 
was calibrated using Image-Pro Plus software. 
Alamarblue assay 
Alamarblue assay, which incorporates a redox indicator that changes color or 
fluorescence in response to cell metabolic activity, is a commonly used method to assess 
cell viability and/or proliferation of mammalian cells(Gonzalez & Tarloff 2001) and 
micro-organisms(Byth et al. 2001). In our studies, 15 overnight cultured islets either 
control FVB islets or transgenic HMT -1 islets were hand picked into 200ul fresh culture 
medium containing 1 :20 diluted AlamarBlue on a 96-well plate. Islets were cultured for 
4hr and the developed AlamarBlue absorbance was measured on a fluorescent microplate 
reader (Tecan) at the excitation wavelength of 535nm and the emission wavelength of 
595nm. After three washes of 200ul fresh culture medium, islets were cultured and 
treated under different oxygen conditions for specified times. At the end of treatment, the 
culture medium was replaced with new 200ul fresh culture medium containing 1 :20 
diluted Alamarblue. The color was developed for another 4hr and the absorbance was 
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measured again. The islet cell viability was calculated from the ratio of the absorbance 
value after treatment over the absorbance value before treatment. 
Apoptotic and Necrotic DNA measurement 
The measurement of apoptotic and necrotic DNA in SNAP treated islets was 
performed by a cell death detection ELISA (Roche) based on the manufacturer 
instruction manual. Basically, 40 to 50 islets were cultured in 500ul fresh culture medium 
in a 1.5ml microtube with or without SNAP treatment for 24hrs. After treatment the 
microtube was centrifuge at 200g for 10 minutes at 4°C. The supernatant was removed as 
the necrosis DNA sample. The pellet was lysed by 1 OOllllysis buffer from the kit for 30 
minutes at room temperature. The microtube was centrifuge again at 200g for lO minutes 
at 4°C. The supernant was removed as apoptotic DNA sample. To quantify the necrotic 
and apoptotic DNA, both DNA samples were added to the streptavidin-coated microplate 
offered in the kit. With the addition of a mixture of anti-histone-biotin and peroxidase-
conjugated anti-DNA antibody followed by 2hrs incubation at room temperature, the 
DNA samples were captured to the microplate by biotinylation. After washing off 
unbound components, the quantitative determination of sample DNA content was carried 
out by measuring conjugated peroxidase activity with ABTS as substrate at 405nm. 
Data analysis 
Data are presented as the mean ± standard error. Statistical significance for two-
group analysis was performed by student's t-test (2-tailed) and for three group analysis 
was performed by ANOVA and Dunnet's post hoc (2-tailed) test. Kaplan-Meier survival 
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analysis and Mantel-Cox Log-rank test were used to analyze islet graft survival time. 





Islet transplantation has been carried in many different sites in recipients, such as 
liver intraportal route, kidney subcapsular site, intraperitoneal spice and small bowel 
subserosal space. In our studies we successfully set up a transplantation method by 
placing the islet graft under kidney capsule. This site is optimal for islet survival in that 
the site beneath the kidney capsule is expected to have sufficient blood supply but have 
less direct interactions with immune system than liver intraportal site does(Brandhorst et 
al. 2001). As shown in Figure 1, the isolated islets from FVB mouse were implanted 
under FVB mouse kidney capsule. Thirty days after transplantation, we recovered the 
islet graft and examined the islet morphology and insulin content by H&E staining and 
immunohistochemistry. We found that the 30-day islet graft still maintained relatively 
normal islet structure and insulin staining. 
To test whether overexpression of MT in the beta cells would improve islet graft 
survival, we first performed an allotransplantation (allotransplantation indicates that the 
grafts were transplanted on to a different strain of mice) study by implanting 400 FVB 
control islets or MT transgenic islets under the renal capsule of STZ induced diabetic 
Balb/c mice. We found that the Balb/c diabetic mice that received a graft of 400 FVB 
islets were brought to euglycemia for a short period of time. However, within about one 
week they returned to hyperglycemia. The average period of euglycemia with an FVB 
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islet graft was 8.36±1.67 days. However, the Balb/c mice that received MT transgenic 
islet grafts remained euglycemic for a much longer time. The period of euglycemia for 
recipients of an MT islet graft is markedly increased to 16.2 ±2.S2 days (Figure 2). We 
also examined nitrotyrosine staining in both MT and FVB islet grafts recovered after 5 
days of transplantation. Nitrotyrosine is recognized as an indicator of protein oxidative 
damage when the tyrosine residues are oxidized by peroxynitrite, a highly potent ROS 
formed by superoxide radical and nitric oxide. In transplantation the production of 
peroxynitrite was greatly increased in the grafts suggesting that peroxynitrite may play an 
important role in graft rejection and loss (MacMillan-Crow et al. 1996). Our data 
confirmed this finding. In Figure 3, the nitrotyrosine staining in control FVB islet graft 
was marked elevated after transplantation. But the antioxidant MT transgene markedly 
reduced the nitrotyrosine production. These data indicate that ROS may be involved in 
the graft damage, at least in the early stage of allotransplantation and the protective effect 
of MT to prolong islet graft survival may be through the elimination of oxidative damage 
by scavenging ROS. 
During allotransplantation the islet grafts are exposed to an environment 
containing a variety of stressors, including immune rejection, glucose toxicity, ischemic 
damage and reperfusion injury. All these processes can induce ROS production. In order 
to differentiate whether the early benefit of the MT transgene is due to the protection 
against ischemic/reperfusion injury or against immune rejection or glucotoxicity, we did 
further syngeneic transplantation studies. In this transplantation model we used FVB 
mice with normal blood glucose levels as recipients, thereby excluding the influence of 
immune rejection and glucose toxicity. Six days after transplantation islet graft was 
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removed from the kidney and the graft insulin content was measured. Graft insulin 
content is a widely used parameter to assess the response of transplanted islets(Montana 
et al. 1993; Jansson et al. 1995). As shown in Figure 4, both FVB and MT islet grafts 
after 6 days of syngeneic transplantation lost part of their insulin contents compared to 
their initial values. However, FVB grafts lost much more insulin than MT islet grafts did. 
MT overexpression protected beta cells by preserving more than 50% of original islet 
insulin, whereas FVB graft lost almost 80% of original insulin. This finding that islet 
grafts lose insulin very much in the early stages of syngeneic transplantation is consistent 
with other reports(Davalli et al. 1996; Xu et al. 1999). During this early stage of 
transplantation, the islet cells in the graft dynamically change their metabolism rate and 
gene expression pattern characterized by substantial islet cell dysfunction and death. 
Ischemia after the transplantation and the following reperfusion during revascularization 
may contribute to this early islet graft failure. Our result that MT protected from early 
islet graft insulin loss indicates that the MT transgene may protect from 
ischemialreperfusion damage after transplantation. This is because ischemia followed by 
reperfusion is known to induce ROS and antioxidants are known to be beneficial for 
preventing reperfusion injury(Li et al. 1997; Wang et al. 2001). 
Hypoxia in vitro studies 
To assess the possible mechanism of MT protection, we carried out in vitro 
studies by exposing isolated FVB and MT islets to hypoxic conditions in a sealed 
chamber. In this chamber only 1 % O2 was included, which is close to the environment 
that the transplanted islets suffer from in the in vivo condition after transplantation. We 
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chose 1 % 02 because Carlsson et al. (Carlsson et al. 2001) recently reported a mean P02 
level was 5-10 mmHg (about 1 % 02) in syngeneically transplanted islets. After exposure 
to the hypoxia condition for 24, 48, and 72hrs, the cell viability of both FVB and MT 
islets was measured with Alamar Blue assay. As shown in Figure 5, the islet cell viability 
in FVB islets was markedly decreased by hypoxia treatment. However the overexpression 
of MT in beta cells significantly inhibited hypoxia induced reduction of cell viability at 
all time points we analyzed. 
Hypoxia and hypoxia followed by reoxygenation is known to induce ROS 
production(Li & Jackson 2002; Duranteau et al. 1998). Therefore it may also be true that 
overexpression of the ROS scavenger, MT, would decrease hypoxia induced ROS 
production in the islet cells. We measured ROS production by a redox state sensitive 
fluorescence dye (CM-H2DCFDA) in both FVB and MT islets treated with hypoxia for 2 
and 7 hr. The data in the Figure 6 demonstrated that hypoxia induced ROS generation in 
both FVB and MT islets. But the ROS levels in MT islets were dramatically lowered by 
the MT trans gene. Hence, the protective effect of MT against hypoxia induced cell 
damage may be through a decrease of ROS production. 
Nitric oxide in vitro studies 
The association between NO production and early islet graft damage has been 
previously described in xenotransplantation(Ketchum et al. 2000). Application of 
selective iNOS inhibitors has been shown to protect from early islet graft failure in rat 
intraportal islet transplantion(Brandhorst et al. 2001). Our immunohistochemistry data of 
nitrotyrosine staining in allotransplantation study support this concept. Our results 
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suggest that NO may be one of the major ROS involved in the early islet graft damage 
after transplantation and NO perhaps is one of the main targets that MT acts on. By 
eliminating the toxic effects of NO, MT is then able to provide protective effect against 
early islet graft destruction. Therefore, to test this hypothesis both FVB and MT islets 
were treated in vitro with a NO donor, SNAP at different concentrations. After treatment 
we analyzed the islet cell viability by observing islet morphology and by measuring 
apoptotic and necrotic islet DNA. We also evaluated the islet function by measuring 
glucose stimulated insulin secretion. 
Visual observation revealed obvious, reproducible differences in the sensitivity of 
MT and FVB islets (Figure 7) to SNAP. FVB islets were visibly damaged at 1 mM 
SNAP and generally disintegrated into single cells at 2 and 3 mM. But MT islets did not 
exhibit a similar degree of damage until the SNAP concentration was raised to 3 mM. 
The apoptotic and necrotic DNA quantification by a photometric enzyme-immunoassay 
confirmed this protective effect of MT. As shown in Figure 8, SNAP treatment induced 
islet DNA cleavage. Both apoptotic DNA and necrotic DNA were greatly increased in 
FVB control islets after exposure to SNAP. However MT islets had markedly reduced 
contents of cleaved DNA, relative to FVB islets. This was especially obvious at 3mM 
SNAP. At this concentration DNA damage in the transgenic MT islets was over 50% 
less than that in FVB control islets. These results imply that one mechanism of preserved 
islet mass by the MT transgene was probably through the protection of islet DNA. 
However further analysis of islet insulin secretion function failed to confirm this 
protective effect of MT. In Figure 9 we exposed both FVB and MT islets to different 
concentrations of SNAP for 12 hrs, and the glucose stimulated insulin secretion was 
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measured. We found SNAP significantly inhibited insulin secretion on both types of 
islets. But no difference in insulin secretion was found between FVB and MT islets. 
Currently we have no good explanation for the discrepancy that MT protected from 
SNAP induced islet DNA damage but not from the inhibition of islet insulin secretion. It 
is very possible that these two effects on islet cells may be through two different 
pathways and MT only has an action on one of them. It is notable that the insulin 
secretion of FVB islets significantly rose at 2 mM SNAP. Since the increase in released 
insulin was seen at both low and high glucose concentrations this was probably not due to 
regulated insulin secretion. This phenomenon might be explained by the fact that at 
2mM SNAP structural integrity of FVB islets was severely damaged (Figure 7). Due to 
this structural damage, beta cell insulin leaked into the media. 
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Figure 1. Islet graft under the kidney capsule one month after syngeneic transplantation. 
In panel A, the white spot is the graft of FVB islets transplanted to FVB recipient mouse. 
Panel B is H&E staining of the graft. Panel C is insulin staining of the graft (Brown 
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Figure 2. Graft survival ofFVB and HMT-l islets transplanted into diabetic Balb/c mice. 
MT overexpression prolongs islet graft survival in allotransplantation. 400 islets were 
transplanted under both kidney capsules of STZ induced diabetic Balb/c mice. Graft 
survival was defined in Methods. The survival time ofHMT-l grafts (16.2 ±2.S2 days) is 
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Figure 3. H&E staining and immunohistochemistry staining of nitrotyrosine in FVB and 
HMT -1 allografts 6 days after transplantation. MT overexpression reduced nitrotyrosine 
production in allotransplantation. A and B show the H&E staining of grafts. Monoclonal 
anti-nitrotyrosine primary antibody was used for nitrotyrosine staining (C, D). Similar 
results were obtained from three independent recipient transplanted mice. Magnification 
x 100. 
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Figure 4. Retained insulin contents in grafts of FVB and HMT-1 islets after syngeneic 
transplantation. MT overexpression protects from graft insulin loss during syngeneic 
transplantation. Islets were transplanted into normal FVB mice and the recovered graft 
insulin levels were measured as described in Methods. Data at 6 days was collected from 
12 recipient FVB mice. The value of MT graft is different from the value of FVB graft, * 
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Figure 5. The MT trans gene increased cell viability during hypoxia. FVB and HMT-l 
islets were treated with hypoxia for 24h, 48h, and 72h. Cell viability was measured by 
alamarblue. Data were calculated from three independent experiments. Where HMT-I 
values are different from the corresponding FVB values, * P<O.05 and ** P<O.Ol by two 
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Figure 6. ROS production in FVB and HMT -1 islets exposed to hypoxia. MT 
overexpression reduced ROS production during hypoxia. FVB and HMT -1 islets were 
treated with hypoxia for 2h or 7h. ROS production was measured using fluorescence dye 
(CM-H2DCFDA). Where HMT-l values are different from the corresponding FVB 
values, * P<O.05 and ** P<O.OI by two tailed Student's t-test. Vertical bars indicate 









Figure 7. Representative photomicrographs of FVB and HMT-I islets after SNAP 
treatment in vitro. Overexpression of MT in HMT-I islets reduced the disruption to 
morphology. FVB and HMT-I islets were exposed to SNAP for 22 h. The concentrations 
of SNAP are shown on the left. Similar results were obtained in four independent 




('1:1 ('1:1 160 ..... ..... 
0 -HMT·1 0 -HMT·1 ..... ..... 
.~ en 20 (I) en 140 
(I) a. .- a. 
0 ... (I) ... 120 -(I) 0(1) 
Q.a. 15 ::;a. 0 
Q.~- cu(l)_ 100 
<cc:::c( c~c( 
('I:Iz "'('I:Iz 80 ... .QC O.QC 
0 ... 10 _ ... 
-0 >cO 60 >cUI cu Ul cu.Q .Q 
"C('I:I "C('I:I 
5 c 40 ':::::IiE -::::liE 
c::: c::: 
." ." 20 
0 0 ...,. ::!.. 0 0 
0 2 3 0 2 3 
SNAP (nIJI) SNAP (nIJI) 
Figure 8. Apoptosis and necrosis in FVB and HMT-l islets exposed to SNAP in vitro. 
MT trans gene reduced both apoptotic and necrotic beta cell death. Isolated islets were 
exposed to the indicated concentrations of SNAP for 22 h. Apoptotic and necrotic DNA 
levels were measured using an anti-histone biotin/anti-DNA POD ELISAplus kit as 
described in Methods. Data were calculated from four independent experiments. Where 
HMT-l values are different from the corresponding FVB values, * P<O.05 and ** P<O.Ol 
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Figure 9. Glucose stimulated insulin secretion from FVB and HMT-l islets exposed to 
SNAP in vitro. MT overexpression does not protect from the inhibitory effect of nitric 
oxide on glucose stimulated insulin secretion. After islets were exposed to the indicated 
concentrations of SNAP for 12 h, basal (3 mM glucose) and high glucose (20 mM) 
stimulated insulin secretions were measured as described in Methods. Data were 
calculated from eight independent assays. No significant difference in insulin secretion 
was found between FVB and HMT -1 islets. It is notable that insulin secretion rose in 
FVB islets at 2 mM SNAP. This is probably due to the damaging effect of SNAP on FVB 




In this study, we explored the effect of overexpression MT in beta cells on the 
outcome of islet transplantation. We demonstrated that MT overexpression could prolong 
graft survival time. The benefit of MT is probably due to the protection from early islet 
graft damage not immune rejection. In addition, a set of in vitro experiments was 
performed to reveal the possible mechanisms of MT protection. Hypoxia in vitro studies 
demonstrated that MT could inhibit hypoxia induced beta cell death and ROS production. 
Further, nitric oxide in vitro studies suggested that islets that overexpressed MT were 
more resistant to nitric oxide induced cytotoxicity, but MT overexpression could not 
protect from nitric oxide induced insulin secretion dysfunction. 
Although the data we presented here only showed that MT doubled islet graft 
survival time in allotransplantation, the result could still be significant for clinic trials of 
islet transplantation. To date islet transplantation has been recognized as a very valuable 
therapy for treatment of type 1 diabetes. Despite a fairly low number of successful 
procedures, when successful, the islet transplantation is able to tightly control blood 
glucose level without insulin therapy and stops deleterious long-term complications. 
However many clinical trials of islet autotransplantation have demonstrated that islet 
grafts fail very soon, usually in the subsequent weeks and months after a short period of 
euglycemia immediately after surgery (White et al. 1998; Farney et al. 1991; Cameron et 
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al. 1980). Since there is no immune rejection during islet autotransplantation, these data 
indicate that the early phase of transplantation might be an important stage for late islet 
engraftment and normal beta cell function. In this stage islet grafts are destroyed by many 
cytotoxic mediators including local activated macrophage, cytokines, nitric oxide and 
ROS. Therefore the early stage of islet graft loss after transplantation might be one of the 
main obstacles for the success of islet transplantation. Looking for approaches to 
overcome this obstacle should be a promising direction of islet transplantation study. In 
our present study, the finding that MT significantly improved islet graft survival both in 
allotransplantation and syngeneic transplantation may indicate that this procedure could 
provide a feasible method to increase the chance of successful islet transplantation. 
Understanding the mechanism of the early graft loss is another important step in 
islet transplantation study. This mechanism could be very complex because after 
transplantation many factors have been shown to be involved in this process of damage. 
This loss is unlikely due to immune rejection because this specific immune reaction 
won't occur normally until two weeks after transplantaion. Therefore, other factors may 
account for the early islet graft damage in our allotransplantation. 
After transplantation the islet graft is under a condition of oxidative stress. 
Chronic hypoxia and ischemialreperfusion are among the reasons leading to this 
oxidative damage. It has been measured that the mean POz is 5-10 mmHg (about 1 % 02) 
in syngeneically transplanted islets 9-12 weeks after implantation, regardless of the 
implantation site(Carlsson et al. 2001). Islet grafts are initially an essentially avascular 
tissue. They are particularly prone to the destruction caused by ischemia followed by 
reperfusion during the process of rev as cuI ariz at ion of the islet grafts(Menger et al. 1992). 
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Low levels of oxygen or a hypoxic environment can impair islet cell function for example 
by inhibiting beta cell insulin biosynthesis. It has been shown that there is a strong 
correlation between reduced oxygen supply and the occurrence of apoptosis in isolated 
human and rat islets(Moritz et al. 2002). The hypoxia in vitro study in the present study 
also demonstrated this point. 
It has been well documented that various ROS including nitric oxide(Reid et al. 
2001) and superoxide(Akizuki et al. 2000) are produced during the early phase of 
transplantation. Both chronic hypoxia, the ischemiafreperfusion process (Li & Jackson 
2002)and the non-specific infiltration of macrophage in the islet graft may contribute to 
ROS generation in the early stages of islet transplantation. Systemic measurement of 
nitrotyrosine production after transplantation indicates that the day for the peak of 
nitrotyrosine production is 7 days after transplantation(Sakurai et al. 1999). Our data 
confirmed these concepts by detecting the ROS production under hypoxia condition and 
by immunostaining of nitrotyrosine in the allotransplanted graft. Consequently ROS 
mediated destruction may be another important factor in the early islet graft loss. 
The pancreatic beta cells contain low levels of ROS scavenger systems(Grankvist 
et al. 1981b; Welsh et al. 1995; Malaisse et al. 1982; Johansson & Borg 1988), therefore 
any approach to reduce oxidative tension in transplanted islet by enhancing their ROS 
defense system is expected to improve islet graft survival. In our study we introduced an 
antioxidant MT transgene specifically in beta cells to increase their ROS scavenging 
capacity. Our results supported the importance of antioxidants and oxidative stress in 
transplantation. These data are consistent with clinical antioxidant trials and recent 
successful reports of antioxidant treatments in islet transplantation(Winter et al. 2002; 
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Bottino et al. 2002). In a very recent study(Bottino et al. 2002) an antioxidant SOD 
mimic was found to greatly increase islet graft survival when this drug was used during 
the isolation of islets. Consequently external application of antioxidants, either by direct 
exposure or gene transfer into isolated islets, might be a very valuable tool to increase the 
efficacy of islet transplantation. 
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• "Pancreatic beta cell antioxidant trans genes in 
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Lecturer 1992-1998 
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students' experiments. 
Effects of fenfluramine combined with electro acupuncture on monoamine release in 
periaqueductal gray of rat brain. Acta Pharmacol Sin 1999,20(7): 597-600 
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Expressions of preproenkephalin mRNA during electroacupuncture analgesia enhanced 
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Alterations of central delta and Kappa opioid receptor binding sites in droperidol 
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Honors 
Outstanding Student Fellowship, 1988, 1990, 1992, SMU, China 
First Prize for the research thesis on the mechanism during electro acupuncture analgesia 
enhanced by fenfluramine, 1994, The Third East-West Panin Conference, XiAn, China 
One of the winners ofthe First Prize for Scientific Technological Development by the 
National Education Commission for the research on relationship between opioidnergic 
and dopaminergic system during electro acupuncture combined with drugs. 1997, 
National Education Commission, China 
One ofthe winners of the Second Prize for Scientific Technological Development by the 
National Education Commission for the research on opioid receptor and its molecular 
mechanism during acupuncture analgesia, 1999, National Education Commission, China 
IPIBS Fellowship, 2001-2002, University of Louisville, 
Honorable Mention for Graduate Student Division, 2001, Research Louisville 2001 
3rd Place Award for Graduate Student Division, 2002, Research Louisville 2002 
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